A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
PURPOSE: The purpose of this study is to evaluate the impact of pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in patients with type 2 diabetes mellitus (T2DM), as compared to usual care by a physician. METHODS: This was a retrosp…
Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden. Once regarded as a condit…
INTRODUCTION: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss. METHODS: Systematic review and network meta-analysis of randomized controlled…
PURPOSE: Metabolically-dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and is strongly linked to obesity and type 2 diabetes mellitus (T2D). Tirzepatide, a dual…
AIMS: There is growing evidence that the GLP-1 system is implicated in alcohol and other substance use disorders, and that GLP-1-based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP-1 b…
BACKGROUND: Overweight and obesity are rising globally. During perimenopause years, declining estrogen and changes in body composition increase visceral fat and insulin resistance, increasing cardiometabolic risk. OBJECTIVE: To estimate trends in ove…
Skin redundancy after massive weight loss often requires body contouring procedures such as abdominoplasty and mastopexy. Bariatric patients may face higher complication risks due to nutritional deficiencies. However, with proper management, includin…
OBJECTIVE: The authors evaluated whether glucagon-like peptide-1 receptor agonists (GLP-1-RAs) improve outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH), spontaneous intracerebral hemorrhage (sICH), and acute ischemic stroke (AIS) a…
Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, insulin resistance, and chronic inflammation resulting in reproductive and metabolic complications. Traditional metfo…
SUMMARY: We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide. Although tirzepatide h…
PURPOSE: This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological…
BACKGROUND: Diabetes mellitus, a global epidemic, necessitates robust evidence synthesis to guide clinical practice. This study analyzes systematic reviews and meta-analyses in diabetes research to identify trends, gaps, and key insights for advancin…
BACKGROUND: Sepsis-associated acute lung injury (ALI) is characterized by unregulated systemic inflammation, disruption of the redox balance, and impaired pulmonary function. Tirzepatide, a synthetic dual GLP-1 and GIP receptor agonist possessing ant…
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its e…
BACKGROUND: In the SURPASS-CVOT trial, tirzepatide, a dual incretin agonist that targets the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, was shown to be non-inferior to dulaglutide for the primary composite car…
INTRODUCTION: With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat-to-target (TtT) thresholds for obesity to the outco…
BACKGROUND: GLP- 1 RA have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1 RA inhibit progression of solid tumor malignancies via dow…
OBJECTIVES: Youth with type 1 diabetes (T1D) and obesity face challenges in achieving optimal glycemic control and experience higher risk for long-term complications. While glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown weight and gly…